Clinical Trials Logo

Soft Tissue Sarcoma clinical trials

View clinical trials related to Soft Tissue Sarcoma.

Filter by:

NCT ID: NCT02867592 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Start date: May 18, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.

NCT ID: NCT02634710 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall

Start date: February 23, 2016
Phase: N/A
Study type: Interventional

This is a nonrandomized Phase II pilot protocol to determine the feasibility, toxicity and disease control (local control, overall and progression-free survival) using hypofractionated preoperative radiation therapy in patients with primary localized soft tissue sarcomas (STS).

NCT ID: NCT02571829 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

Start date: May 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether ribociclib are effective and safe in the treatment of progressive well/dedifferentiated liposarcoma (WDL/DDL).

NCT ID: NCT02451943 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

ANNOUNCE
Start date: September 14, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma.

NCT ID: NCT02449343 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

Study of Anlotinib in Patients With Soft Tissue Sarcoma(STS)(ALTER0203)

Start date: May 12, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.

NCT ID: NCT02432963 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Start date: June 14, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that have failed prior therapy, and that cannot be removed by surgery. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving vaccine therapy together with pembrolizumab may be a better treatment in patients with solid tumors.

NCT ID: NCT01807468 Active, not recruiting - Neuroblastoma Clinical Trials

Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors

Start date: May 2013
Phase: Phase 2
Study type: Interventional

To evaluate feasibility and efficacy of haploidentical stem cell transplantation in patients with high-risk solid tumors who failed after tandem high-dose chemotherapy and autologous stem cell transplantation. To evaluate feasibility and efficacy of NK cell infusion after haploidentical stem cell transplantation in patients with high-risk solid tumors who failed after tandem high-dose chemotherapy and autologous stem cell transplantation.

NCT ID: NCT01803152 Active, not recruiting - Sarcoma Clinical Trials

Dendritic Cell Vaccine for Children and Adults With Sarcoma

Start date: January 6, 2014
Phase: Phase 1
Study type: Interventional

The purpose if this study is to evaluate an investigational vaccine using patient-derived dendritic cells (DC), a type of white blood cell that helps fight infections in the body, (DC) (a vaccine made out of participants' own cells and tumor) to treat sarcoma.

NCT ID: NCT01458249 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

An Open Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced Soft Tissue Sarcoma (Study E7389-J081-217)

Start date: November 2011
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of eribulin mesylate in subjects with soft tissue sarcoma who received at least one standard chemotherapy (an anthracycline or an ifosfamide monotherapy or a combination therapy).

NCT ID: NCT01347034 Active, not recruiting - Soft Tissue Sarcoma Clinical Trials

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

Start date: January 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if injection of the participant's our own immune related white blood cells (called dendritic cells) into their tumor will strengthen their immune system to fight against their cancer.